Invention Grant
- Patent Title: Prolyl hydroxylase inhibitors
-
Application No.: US15187075Application Date: 2016-06-20
-
Publication No.: US10035779B2Publication Date: 2018-07-31
- Inventor: Duke M. Fitch , Antony N. Shaw , Kenneth Wiggall
- Applicant: GlaxoSmithKline, LLC
- Applicant Address: US DE Wilmington
- Assignee: GlaxoSmithKline, LLC
- Current Assignee: GlaxoSmithKline, LLC
- Current Assignee Address: US DE Wilmington
- Agent Loretta J. Sauermelch; Edward R. Gimmi
- Main IPC: C07D239/60
- IPC: C07D239/60 ; A61K31/515 ; C07D239/54 ; C07D239/62 ; C07D401/04 ; C07D405/04 ; C07D405/10 ; C07D409/04 ; C07D409/10 ; C07D413/06 ; C07D413/10 ; C07D417/10 ; C07D239/22

Abstract:
The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
Public/Granted literature
- US20160297772A1 PROLYL HYDROXYLASE INHIBITORS Public/Granted day:2016-10-13
Information query